GYRE

Gyre Therapeutics Inc.

GYRE.US gyretx.com + Research + Basket
CIK 0001124105
Employees 625
Phone 858-284-0115
Fiscal year end December
IPO Apr 12, 2006
Address 12730 High Bluff Drive, San Diego, CA, United States, 92130
6.83
+0.30 (+4.59%)
USD · NASDAQ
52-week range
5.44
9.14
Trading at 38% of the 52-week range
Market Cap
692.40M
P/E Ratio
0.00
Forward P/E
188.68
Book Value
1.02
Div. Yield
N/A
% Institutions
8.24%
% Insiders
74.40%

1 Year

-18.6%

3 Year

-14.6%

10 Year

-93.5%
Description

Gyre Therapeutics, Inc., a pharmaceutical company, engages in the development and commercialization of small-molecule, anti-inflammatory, and anti-fibrotic drugs targeting organ fibrosis. The company offers ETUARY (Pirfenidone), an anti-fibrotic drug approved for the treatment of idiopathic pulmonary fibrosis; and under Phase 3 trials for the treatment of pneumoconiosis. It is also involved in the development of F351 (Hydronidone), a structural derivative of ETUARY under Phase 3 trials for the treatment of chronic hepatitis B (CHB)-associated liver fibrosis; and completed Phase 1 trials for the treatment of liver fibrosis associated with metabolic dysfunction-associated steatohepatitis. In addition, the company develops F573, which is in Phase 2 clinical trials for the treatment of acute/acute-on-chronic liver failure. Further, its preclinical products include F230 for the treatment of pulmonary arterial hypertension; and F528 to treat chronic obstructive pulmonary disease. Gyre Therapeutics, Inc. was founded in 2002 and is headquartered in San Diego, California. Gyre Therapeutics, Inc. operates as a subsidiary of GNI USA, Inc.

Actions

Add an action for GYRE.US, or sign in to see your action list.

People

▼

Directors & Officers

Name Title Year Born
Mr. Thomas W. Eastling M.D. Chief Financial Officer 1959
Mr. Weiguo Ye Chief Operating Officer 1978
Ms. Ruoyu Chen Chief Information Officer 1971
Dr. Ying Luo Ph.D. CEO, President & Director 1965
Dr. Yue Xiong Ph.D. Chief Scientific Officer & Director NA
Mr. Joshua Bergmann J.D. General Counsel & Corporate Secretary NA
Seth Goldblum M.B.A. Senior Vice President of Corporate Development NA
Mr. Jialiang Wang Ph.D. Executive VP & GM NA
Jing Liu Ph.D. Senior Vice President of Platform Chemistry NA
Mark Marino Senior Vice President of Clinical Development NA

Insider Trading

Open insider trading
Date Insider Name Title Transaction Type Shares Price Value SEC
May 23, 2025 Songjiang Ma N/A Sale 182.00 $10.24 $1.86K SEC
May 22, 2025 Songjiang Ma N/A Sale 2.00K $10.97 $21.94K SEC

Shareholders

▼

Institutional Holders

Holder Name Shares Date Reported % Out Value % Change
HSG Holding Ltd 3.75M Jun 30, 2026 3.54% $2.06 0.00%
BlackRock Inc 993.94K Jun 30, 2026 0.94% $0.00 31.02%
Octagon Capital Advisors LP 954.42K Jun 30, 2026 0.90% $0.57 0.00%
Vanguard Capital Management, LLC 876.93K Jun 30, 2026 0.83% $0.00 -10.90%
Geode Capital Management, LLC 532.95K Jun 30, 2026 0.50% $0.00 23.54%
State Street Corp 245.40K Jun 30, 2026 0.23% $0.00 13.44%
Charles Schwab Investment Management Inc 184.29K Jun 30, 2026 0.17% $0.00 11.53%
Northern Trust Corp 169.54K Jun 30, 2026 0.16% $0.00 26.67%
SBI Securities Co Ltd 166.75K Jun 30, 2026 0.16% $0.03 -2.39%
Vanguard Fiduciary Trust Co 151.07K Jun 30, 2026 0.14% $0.00 9.73%
Vanguard Portfolio Management, LLC 123.95K Jun 30, 2026 0.12% $0.00 77.55%
The Goldman Sachs Group Inc 86.24K Jun 30, 2026 0.08% $0.00 17.93%
Bank of New York Mellon Corp 62.75K Jun 30, 2026 0.06% $0.00 45.44%
Morgan Stanley - Brokerage Accounts 41.69K Jun 30, 2026 0.04% $0.00 382.48%
STRS OHIO 25.80K Jun 30, 2026 0.02% $0.00 22.27%
Dimensional Fund Advisors, Inc. 25.27K Jun 30, 2026 0.02% $0.00 0.00%
AllianceBernstein L.P. 24.59K Jun 30, 2026 0.02% $0.00 12.64%
Nuveen, LLC 24.51K Jun 30, 2026 0.02% $0.00 0.00%
UBS Group AG 18.76K Jun 30, 2026 0.02% $0.00 -11.02%
Millennium Management LLC 18.49K Jun 30, 2026 0.02% $0.00 0.00%

Fund Holdings

Rank Holder Name Shares Held % of Shares Change Date Reported
1 Vanguard MStar Total Stk Mkt Idx Invest 1.04M 0.98% ▲ 69.64% Sep 30, 2026
2 iShares Russell 2000 ETF 396.32K 0.37% ▼ 1.13% Sep 30, 2026
3 Fidelity Small Cap Index 199.91K 0.19% ▼ 0.12% Jul 31, 2026
4 Schwab US Small-Cap ETF™ 184.52K 0.17% ▲ 0.06% Sep 30, 2026
5 Fidelity Extended Market Index 110.28K 0.10% ▼ 0.53% Aug 31, 2026
6 iShares Russell 2000 Growth ETF 100.60K 0.09% ▼ 0.13% Sep 30, 2026
7 Vanguard Russell 2000 ETF 90.61K 0.09% ▼ 14.32% Sep 30, 2026
8 Fidelity Nasdaq Composite Index 62.21K 0.06% ▲ 0.00% Aug 31, 2026
9 Multimanager Aggressive Equity IA 43.20K 0.04% ▲ 0.00% Aug 31, 2026
10 iShares Russell 2000 Value ETF 41.89K 0.04% ▲ 0.15% Sep 30, 2026

Financial Highlights

▼
Market Cap: $692.40M
EBITDA: $-12.13M
Book Value: $1.02
Earnings/Share: $-0.25
Profit Margin: -19.33%
Operating Margin: -47.62%
ROA (TTM): -5.42%
ROE (TTM): -17.44%
Revenue (TTM): $109.82M
Revenue/Share (TTM): $1.17
Earnings Growth (YOY): 166.20%
Revenue Growth (YOY): -2.10%

Valuation Metrics

Enterprise Value: $573.31M
Trailing P/E: 0.00
Forward P/E: 188.68

Shares Statistics

Shares Outstanding: 106.03M
Shares Float: 35.94M
% Insiders: 74.40%
% Institutions: 8.24%
Short % Float: 6.45%

Stock Price History

▼

1 Year Price History

3 Years Price History

10 Years Price History

Max Price History

Financial Charts

▼
Open balance sheet Open capital intensity Download Financials (Excel)

Revenue, Net Income & Operating Cash Flow (Yearly)

Change % vs Prior Year

Revenue, Net Income & Operating Cash Flow (Quarterly)

Change % vs Prior Quarter

Operating Expenses (Yearly)

Operating Expenses (Quarterly)

Balance Sheet (Yearly)

Balance Sheet (Quarterly)

Assets Breakdown (Yearly)

Assets Breakdown (Quarterly)

Liabilities Breakdown (Yearly)

Liabilities Breakdown (Quarterly)

Income Statement Waterfall

▼
Open full waterfall Open balance sheet
Line Item
Step Type
Value
Revenue
adjust
$116.59M
Cost of Goods Sold
adjust
$-5.42M
Gross Profit
subtotal
$111.17M
SG&A
adjust
$-20.80M
R&D
adjust
$-13.70M
Other Operating Expense
adjust
$-65.18M
Operating Income
subtotal
$11.49M
Other / Non-Operating Items
adjust
$-6.46M
Net Income
subtotal
$5.03M

Earnings Per Share (EPS) History

▼

Financial Ratios

▼

📦 Raw API Data (JSON Explorer)

▼

Assistant

×
Hello! I'm your AI assistant. I have access to the financial data on this page. Ask me anything about GYRE.US!